These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

379 related articles for article (PubMed ID: 17391310)

  • 1. Retrospective nationwide survey of Japanese patients with transfusion-dependent MDS and aplastic anemia highlights the negative impact of iron overload on morbidity/mortality.
    Takatoku M; Uchiyama T; Okamoto S; Kanakura Y; Sawada K; Tomonaga M; Nakao S; Nakahata T; Harada M; Murate T; Ozawa K;
    Eur J Haematol; 2007 Jun; 78(6):487-94. PubMed ID: 17391310
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The deleterious effects of iron overload in patients with myelodysplastic syndromes.
    Dreyfus F
    Blood Rev; 2008 Dec; 22 Suppl 2():S29-34. PubMed ID: 19059054
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Iron status and treatment modalities in transfusion-dependent patients with myelodysplastic syndromes.
    Delforge M; Selleslag D; Triffet A; Mineur P; Bries G; Graux C; Trullemans F; MacDonald K; Abraham I; Pluymers W; Ravoet C
    Ann Hematol; 2011 Jun; 90(6):655-66. PubMed ID: 21318574
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Correction of anemia in a transfusion-dependent patient with primary myelofibrosis receiving iron chelation therapy with deferasirox (Exjade, ICL670).
    Di Tucci AA; Murru R; Alberti D; Rabault B; Deplano S; Angelucci E
    Eur J Haematol; 2007 Jun; 78(6):540-2. PubMed ID: 17391307
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Myocardial iron loading by magnetic resonance imaging T2* in good prognostic myelodysplastic syndrome patients on long-term blood transfusions.
    Chacko J; Pennell DJ; Tanner MA; Hamblin TJ; Wonke B; Levy T; Thomas PW; Killick SB
    Br J Haematol; 2007 Sep; 138(5):587-93. PubMed ID: 17610536
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term efficacy of deferoxamine iron chelation therapy in adults with acquired transfusional iron overload.
    Schafer AI; Rabinowe S; Le Boff MS; Bridges K; Cheron RG; Dluhy R
    Arch Intern Med; 1985 Jul; 145(7):1217-21. PubMed ID: 3925909
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Outcomes, utilization, and costs among thalassemia and sickle cell disease patients receiving deferoxamine therapy in the United States.
    Delea TE; Hagiwara M; Thomas SK; Baladi JF; Phatak PD; Coates TD
    Am J Hematol; 2008 Apr; 83(4):263-70. PubMed ID: 17924547
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Deferasirox improves hematologic and hepatic function with effective reduction of serum ferritin and liver iron concentration in transfusional iron overload patients with myelodysplastic syndrome or aplastic anemia.
    Cheong JW; Kim HJ; Lee KH; Yoon SS; Lee JH; Park HS; Kim HY; Shim H; Seong CM; Kim CS; Chung J; Hyun MS; Jo DY; Jung CW; Sohn SK; Yoon HJ; Kim BS; Joo YD; Park CY; Min YH;
    Transfusion; 2014 Jun; 54(6):1542-51. PubMed ID: 24313463
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Understanding iron overload: screening, monitoring, and caring for patients with transfusion-dependent anemias.
    Ault P; Jones K
    Clin J Oncol Nurs; 2009 Oct; 13(5):511-7. PubMed ID: 19793708
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment of transfusional iron overload in patients with myelodysplastic syndrome or severe anemia: data from multicenter clinical practices.
    Raptis A; Duh MS; Wang ST; Dial E; Fanourgiakis I; Fortner B; Paley C; Mody-Patel N; Corral M; Scott J
    Transfusion; 2010 Jan; 50(1):190-9. PubMed ID: 19719471
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Iron overload and chelation therapy in patients with low-risk myelodysplastic syndromes with transfusion requirements.
    Remacha AF; Arrizabalaga B; Del Cañizo C; Sanz G; Villegas A
    Ann Hematol; 2010 Feb; 89(2):147-54. PubMed ID: 19690857
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Does iron chelation therapy improve survival in regularly transfused lower risk MDS patients? A multicenter study by the GFM (Groupe Francophone des Myélodysplasies).
    Rose C; Brechignac S; Vassilief D; Pascal L; Stamatoullas A; Guerci A; Larbaa D; Dreyfus F; Beyne-Rauzy O; Chaury MP; Roy L; Cheze S; Morel P; Fenaux P;
    Leuk Res; 2010 Jul; 34(7):864-70. PubMed ID: 20129667
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Red blood cell transfusion therapy and iron chelation in patients with myelodysplastic syndromes.
    Malcovati L
    Clin Lymphoma Myeloma; 2009; 9 Suppl 3():S305-11. PubMed ID: 19778858
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Observational Monitoring of Patients with Aplastic Anemia and Low/Intermediate-1 Risk of Myelodysplastic Syndromes Complicated with Iron Overload.
    Du Y; Long Z; Chen M; Han B; Hou B; Feng F
    Acta Haematol; 2017; 138(2):119-128. PubMed ID: 28866669
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Toward resolving the unsettled role of iron chelation therapy in myelodysplastic syndromes.
    Merkel DG; Nagler A
    Expert Rev Anticancer Ther; 2014 Jul; 14(7):817-29. PubMed ID: 24641787
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Improving clinical outcome in patients with myelodysplastic syndrome and iron overload using iron chelation therapy.
    Leitch HA
    Leuk Res; 2007 Dec; 31 Suppl 3():S7-9. PubMed ID: 18037416
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Controversies surrounding iron chelation therapy for MDS.
    Leitch HA
    Blood Rev; 2011 Jan; 25(1):17-31. PubMed ID: 21030120
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Improved survival in red blood cell transfusion dependent patients with primary myelofibrosis (PMF) receiving iron chelation therapy.
    Leitch HA; Chase JM; Goodman TA; Ezzat H; Rollins MD; Wong DH; Badawi M; Leger CS; Ramadan KM; Barnett MJ; Foltz LM; Vickars LM
    Hematol Oncol; 2010 Mar; 28(1):40-8. PubMed ID: 19557769
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Iron chelation therapy associated with improvement of hematopoiesis in transfusion-dependent patients.
    Oliva EN; Ronco F; Marino A; Alati C; Praticò G; Nobile F
    Transfusion; 2010 Jul; 50(7):1568-70. PubMed ID: 20230535
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adequate iron chelation therapy for at least six months improves survival in transfusion-dependent patients with lower risk myelodysplastic syndromes.
    Delforge M; Selleslag D; Beguin Y; Triffet A; Mineur P; Theunissen K; Graux C; Trullemans F; Boulet D; Van Eygen K; Noens L; Van Steenweghen S; Lemmens J; Pierre P; D'hondt R; Ferrant A; Deeren D; Van De Velde A; Wynendaele W; André M; De Bock R; Efira A; Breems D; Deweweire A; Geldhof K; Pluymers W; Harrington A; MacDonald K; Abraham I; Ravoet C
    Leuk Res; 2014 May; 38(5):557-63. PubMed ID: 24661630
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.